Syensqo 2025 Financial Calendar

Udgivet den 03-09-2024  |  kl. 06:30  |  

Syensqo 2025 Financial Calendar

Brussels, Belgium - September 3, 2024 - 08:30 CET

Syensqo today publishes its 2025 financial calendar and invites the financial community to mark their calendar accordingly. 

Event Date
Full year 2024 earnings  February 24, 2025
Ordinary General Shareholders' Meeting May 6, 2025
First quarter 2025 earnings  May 15, 2025
First half year 2025 earnings  July 31, 2025
First nine months 2025 earnings  November 6, 2025


Quiet period dates will be provided prior to each earnings' season.

Safe harbor

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

About Syensqo 

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates. 
Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Investor Relations Resources

Earnings materials
Strategy
Share information
Credit information
Separation documents
Webcasts, podcasts and presentations
2023 Annual Integrated Report
Subscribe to our distribution list

Contacts

Investors & Analysts Media 
Sherief Bakr
+44 7920 575 989

Bisser Alexandrov
+33 607 635 280

investor.relations@syensqo.com
Perrine Marchal
+32 478 32 62 72

Laetitia Schreiber
+32 487 74 38 07

media.relations@syensqo.com
 

Attachment

20240903_2025_Financial Calendar_EN

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:46 Europa/lukning: Solide regnskaber overskyggede frygt for handelskrig
17:16 Den danske valutareserve faldt en smule i januar - Nationalbanken har ikke interveneret
17:04 Tirsdagens aktier: Bavarian fik på hatten efter skuffende prognose i positivt marked
17:00 Tirsdagens obligationer: Ro på rentemarkedet efter opblødning i handelskrig
15:52 Merck skaber investorpanik med stop for leverancer af kræftvaccine til Kina
15:44 USA/åbning: Wall Street åbner fladt efter udskudt handelskrig - Merck dog i markant drop
15:32 ECB's Villeroy ser sandsynlighed for flere rentenedsættelser
14:58 Nykredit får tilladelse til opkøb af Spar Nord fra Finanstilsynet
14:41 USA/tendens: Nervøse investorer holder øje med handelskrig inden store regnskaber
13:58 Nordnet om kundefavoritter: Novo og kvantecomputere stak ud i januar
13:26 Europa/middag: Solide regnskaber overskygger frygt for handelskrig
12:55 Merck & Co skuffer med prognosen - aktien falder 5 pct.
12:07 Obligationer/middag: Renten står i stampe inden jobvarsel
11:41 Aktier/middag: Bavarian sendt til tælling på "forsigtig" prognose i nervøst marked
11:22 DSV's topchef ser strategi sikre mindre volumentab ved Schenker-opkøb
11:14 Riksbanken-chef ser ledende rente som tilstrækkeligt lav for nu
10:53 Coloplasts topchef har koldt vand i blodet omkring mulig amerikansk told
10:45 Riksbanken-chef: Renten er formentlig sænket tilstrækkeligt nu
10:07 Bavarian Nordic arbejder for at undgå overraskelser efter aktiechok
10:05 Coloplast-topchef: Fornuftig start på året - kan med lidt held indhente det tabte i Urologi